Glial Tumors
Conditions
Keywords
Glial Tumors
Brief summary
The aim of this study is to introduce appropriate assessment instruments and to define patients with gliomas according to cognitive functioning and quality of life. The study will evaluate cognitive functioning as a prognostic factor for survival in patients with glial tumors and will support optimization of treatment strategies to improve patients' quality of life.
Detailed description
This prospective cohort study will assess cognitive functioning and quality of life in patients with glial tumors. The objective is to determine the prognostic value of cognitive functioning on survival, establish appropriate assessment instruments, and contribute to treatment adaptation with the goal of improving quality of life in these patients.
Interventions
OTHERCognitive Functioning and Quality of Life Assessment
Assessment of cognitive functioning and quality of life in patients with glial tumors to evaluate their prognostic value and impact on survival outcomes.
Sponsors
Institute of Oncology Ljubljana
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult participants (≥18 years) * Patients with histologically confirmed glial tumour * Ability to understand the study procedures and provide written informed consent * Ability to complete quality of life questionnaires and cognitive testing
Exclusion criteria
* Age \<18 years * Inability to provide informed consent * Severe cognitive impairment or clinical condition preventing completion of questionnaires and cognitive testing * Insufficient language proficiency to complete the questionnaires and neuropsychological testing
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Quality of Life Score (EORTC QLQ-C30 and QLQ-BN20) | Baseline (before treatment); 6 weeks; 3 months; 6 months; 12 months | Quality of life will be assessed using the European Organisation for Research and Treatment of Cancer questionnaires EORTC QLQ-C30 and the brain cancer module EORTC QLQ-BN20. Scores range from 0 to 100 points. The outcome will be reported as mean change in questionnaire score (points) from baseline to each follow-up assessment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Cognitive Function Test Performance (Neuropsychological Test Battery) | Baseline (before treatment); 6 weeks; 3 months; 6 months; 12 months | Cognitive functioning will be assessed using a neuropsychological test battery evaluating multiple cognitive domains (e.g., language, memory, executive functioning). The outcome will be reported as mean change in test scores from baseline to each follow-up assessment. |
Countries
Slovenia
Outcome results
None listed